Insider Trading activities of Eidos Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eidos Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Eidos Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Eidos Therapeutics, Inc. since 2005. The reporting company's ticker symbol is EIDX. The reporting company's CIK number is 1731831.
The total value of stock buying since 2005 is $129,589,926.
The total value of stock sales since 2005 is $1,102,471.
The total value of stock option exercises since 2005 is $0.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Eidos Therapeutics, Inc. (EIDX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-12 2,853,848 $42,589,910 80,144 $1,102,471 0 $0
2018-06 5,117,648 $87,000,016 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Eidos Therapeutics, Inc. insiders (EIDX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-12-07 Bridgebio Pharma Llc (10% Owner) Sale 41,174 14.15 582,612
2018-12-06 Bridgebio Pharma Llc (10% Owner) Sale 38,970 13.34 519,859
2018-12-05 Bridgebio Pharma Llc (10% Owner) Buy 1,103,848 14.01 15,464,910
2018-12-03 Bridgebio Pharma Llc (10% Owner) Buy 1,750,000 15.50 27,125,000
2018-06-22 Bridgebio Pharma Llc (10% Owner) Buy 1,000,000 17.00 17,000,000
2018-06-22 Kumar Neil (Chief Executive Officer) Buy 1,000,000 17.00 17,000,000
2018-06-22 Satvat Ali J. (Director) Buy 1,000,000 17.00 17,000,000
2018-06-22 Shah Rajeev M. (Director) Buy 1,058,824 17.00 18,000,008
2018-06-22 Kolchinsky Peter Buy 1,058,824 17.00 18,000,008

Insider trading activities including stock purchases, stock sales, and option exercises of EIDX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Eidos Therapeutics, Inc. (symbol EIDX, CIK number 1731831) see the Securities and Exchange Commission (SEC) website.